Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: Rationale/design of peptic ulcer bleed study

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 8, 2008, Pages 666-677

  Sung, J J Y ^a,h   Mossner J ^b   Barkun, A ^c   Kuipers, E J ^d   Lau, J ^a   Jensen, D ^e   Stuart, R ^f   Junghard, O ^g   Olsson, G ^g  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PLACEBO;

ARTICLE; BLOOD TRANSFUSION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; FEMALE; GASTROINTESTINAL SURGERY; HIGH RISK PATIENT; HOMEOSTASIS; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER HEMORRHAGE; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 40949089738     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03631.x     Document Type: Article

References (49)

1. Higham J, Kang J-Y, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of hemorrhage among older subjects. Gut 2002 50:460 4.
2. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003 98:1494 9.
3. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004 99:1238 46.
4. Palmer KR. Non-variceal upper gastrointestinal haemorrhage: guidelines. British Society of Gastroenterology Endoscopy Committee. Gut 2002 51 (Suppl. 4 iv1 6.
5. Barkun A, Bardou M, Marshall JK, Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003 139:843 57.
6. Jensen DM. Treatment of patients at high risk for recurrent bleeding from a peptic ulcer. Ann Intern Med 2003 139:294 5.
7. Kurata JH, Corboy ED. Current peptic ulcer time trends: an epidemiological profile. J Clin Gastroenterol 1988 10:259 68.
8. Thomsen RW, Riis A, Christensen S, Nørgaard M, Sørensen HT. Diabetes and 30-day mortality from peptic ulcer bleeding and perforation: a Danish population-based cohort study. Diabetes Care 2006 29:805 10.
9. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995 311:222 6.
10. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 2006 23:1587 93.
11. Esrailian E, Gralnek IM. Nonvariceal upper gastrointestinal bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am 2005 34:589 605.
12. Green FW Jr., Kaplan MM, Curtis LE, Levin PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978 74:38 43.
13. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut 1989 30:1704 7.
14. Barkun AN, Cockeram AW, Plourde V, Fedorak RN. Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999 13:1565 84.
15. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 1990 31:514 7.
16. Labenz J, Peitz U, Leusing C, Tillenburg B, Blum AL, Börsch G. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997 40:36 41.
17. Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998 158:54 8.
18. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000 343:310 6.
19. 2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 1985 313:660 6.
20. 2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002 16:1137 42.
21. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged therapy? Gastroenterology 1994 106:60 4.
22. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999 94:351 7.
23. Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord 2005 5 (Suppl. 2 S18 30.
24. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992 304:143 7.
25. Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997 32:328 33.
26. Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 1997 32:320 7.
27. Jensen DM, Pace SC, Soffer E, Comer GM, 315 Study Group. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter, randomized, double-blind study. Am J Gastroenterol 2006 101:1991 9.
28. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997 336:1054 8.
29. Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001 111:280 4.
30. Michel P, Duhamel C, Bazin B, et al. Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study. Gastroenterol Clin Biol 1994 18:1102 5.
31. Coraggio F, Rotondano G, Marmo R, et al. Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Eur J Gastroenterol Hepatol 1998 10:673 6.
32. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003 17:211 6.
33. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006 1:CD002094.
34. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia: a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005 21:1055 61.
35. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005 20:153 67.
36. Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98:2616 20.
37. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 60:531 9.
38. Wilder-Smith CH, Röhss K, Bondarov P, Hallerbäck B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment Pharmacol Ther 2004 20:1099 104.
39. Hartmann D, Eickhoff A, Damian U, Riemann JF, Schilling D. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. Eur J Gastroenterol Hepatol 2007 19:133 7.
40. Röhss K, Wilder-Smith C, Kilhamn J, Fjellman M, Lind T. Suppression of gastric acid with intravenous esomeprazole or omeprazole: results of 3 studies in healthy subjects. Int J Clin Pharmacol Ther 2007 45:345 54.
41. Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974 2:394 7.
42. Lau JY, Chung SC, Leung JW, Lo KK, Yung MY, Li AK. The evolution of stigmata of hemorrhage in bleeding peptic ulcers: a sequential endoscopic study. Endoscopy 1998 30:513 8.
43. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007 132:2320 7.
44. Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. J Gastroenterol Hepatol 2005 20:11 25.
45. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol 2006 21:1763 5.
46. van Herwaarden MA, Samsom M, Van Nispen CH, Mulder PG, Smout AJ. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999 13:731 40.
47. Lam SK, Hasan M, Sircus W, Wong J, Ong GB, Prescott RJ. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980 21:324 8.
48. Caraco Y, Lagerstrom PO, Wood AJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996 60:157 67.
49. Caraco Y, Wilkinson GR, Wood AJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996 60:396 404.